Table 5.
Baseline patient characteristics stratified by the presence or absence of RASI therapy in non-IMR patients
| Characteristics | Unadjusted data | IPTW | ||
| RASI (+) (n=403) |
RASI (−) (n=102) |
P value | P value | |
| Age, years, mean±SD | 62±12 | 65±12 | 0.11 | 0.94 |
| Gender, male/female | 334/69 | 87/15 | 0.55 | 0.26 |
| Cardiovascular risk factors | ||||
| Hypertension, n (%) | 230 (57) | 46 (45) | 0.03 | 0.83 |
| Diabetes mellitus, n (%) | 131 (33) | 26 (25) | 0.17 | 0.48 |
| Dyslipidaemia, n (%) | 181 (45) | 48 (47) | 0.70 | 0.83 |
| Current smoker, n (%) | 173 (43) | 36 (35) | 0.16 | 0.34 |
| Frailty | 8 (2) | 5 (5) | 0.10 | 0.80 |
| BMI, kg/m2, mean±SD | 24.5±3.6 | 22.9±3.3 | <0.001 | 0.16 |
| ST segment elevation MI, n (%) | 316 (78) | 76 (75) | 0.40 | 0.99 |
| Killip classification, n (%) | 1.2±0.5 | 1.2±0.6 | 0.56 | 0.91 |
| Prior MI, n (%) | 32 (8) | 6 (6) | 0.47 | 0.63 |
| Primary PCI, n (%) | 366 (91) | 81 (79) | 0.003 | 0.55 |
| CABG, n (%) | 7 (2) | 14 (14) | <0.001 | 0.93 |
| Peak CK, IU/L | 2380±2641 | 2194±2417 | 0.52 | 0.96 |
| Serum creatinine, mg/dL | 1.05±0.97 | 1.07±0.39 | 0.85 | 0.67 |
| eGFR, mL/min/1.73 m2 | 52±18 | 49±21 | 0.10 | 0.01 |
| ACEI, n (%) | 296 (73) | 0 (0) | <0.001 | <0.001 |
| ARB, n (%) | 107 (27) | 0 (0) | <0.001 | <0.001 |
| β-blocker, n (%) | 315 (78) | 66 (65) | 0.01 | 0.96 |
| Statins, n (%) | 266 (66) | 58 (57) | 0.09 | 0.78 |
| Initial TIMI grade flow 3, n(%) | 81 (20) | 21 (21) | 0.91 | 0.68 |
| Anterior MI, n (%) | 216 (54) | 40 (39) | 0.01 | 0.69 |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CK, creatine kinase; eGFR, estimated glomerular filtration rate; IMR, ischaemic mitral regurgitation; MI, myocardial infarction; PCI, percutaneous coronary intervention; RASI, renin–angiotensin system inhibitor; TIMI, Thrombolysis In Myocardial Infarction.